RE:RE:MonographJAZZ cannot do anything legally against anyone until a product is $commercialized$ and generating revenues. You can basically do anything you want, even if covered by a plethora of patents, the trigger point for legal action comes when you commercialize it, by definition, making money. A patent holder then can require you to 'license' and pay royalties.
So imho, we will see (assuming it is a generic version of Epidiolex and better yet, over the counter) a product being commercialized first. Just because a pharma is doing 'development' work does not mean it has breached or infringed on any patents. You need your work to generate $$revenues$$.
Recall LABS saying they identified all 100 compounds in their DMF...that is significant imho when you have the reseach work behind you identifying those 4 or 5 compounds that work together for the entourage effect (reference Dr. David Meiri, U of Technion and breast cancer tumor research).
I also believe the Epidiolex story is just one big teaser to a much larger story yet to unfold for LABS shareholders.